Functional interaction between opioid and cannabinoid receptors in drug self-administration

Journal of Neuroscience

Volumn 21, Issue 14, 2001, Pages 5344-5350

  Navarro, M ^a   Carrera, M R A ^b   Fratta, W ^c   Valverde, O ^d   Cossu, G ^c   Fattore, L ^c   Chowen, J A ^e   Gomez R ^a   Del Arco, I ^a,f   Villanua M A ^a   Maldonado, R ^d   Koob, G F ^b   Rodriguez De Fonseca F ^a,f  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d UNIVERSITAT POMPEU FABRA   (Spain)

^e INSTITUTO CAJAL   (Spain)

^f HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Addiction; Cannabinoid; Drug abuse; Mice; Opioid; Rat; Self administration

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; DIAMORPHINE; MORPHINE; NALOXONE; OPIATE; OPIATE ANTAGONIST; RIMONABANT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SELF ADMINISTRATION; MALE; NEUROPHARMACOLOGY; NONHUMAN; NUCLEUS ACCUMBENS; OPIATE ADDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; RAT; RECEPTOR BLOCKING; REINFORCEMENT; REWARD; WITHDRAWAL SYNDROME;

EID: 0035879079     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.21-14-05344.2001     Document Type: Article

References (61)

1. Endogenous opioids: Biology and function
2. Down-regulation of cannabinoid receptor agonist-stimulated [35S]-GTPγS binding in synaptic plasma membrane from chronic ethanol-exposed mouse
3. Genetic analysis of drug addiction: The role of the cAMP response element binding protein
4. Anatomically specific changes in the expression of somatostatin, growth hormone-releasing hormone and growth hormone receptor mRNA in diabetic rats
5. Intravenous drug self-administration techniques in animals
6. Heroin self-administration in dependent Wistar rats: Increased sensitivity to naloxone
7. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats
8. 9tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats, as measured by intracerebral microdialysis
9. Reduction of voluntary ethanol intake in ethanolpreferring sP rats by the cannabinoid antagonist SR 141716
10. Cannabinoid receptor gene (CNR1): Association with iv drug use
11. Expression of mu opioid receptor mRNA in the rat brain: An in situ hybridization study at the single cell level
12. Determination and characterization of a cannabinoid receptor in rat brain
13. Isolation and structure of a brain constituent that binds to the cannabinoid receptor
14. Profound decrease of mesolimbic dopaminergic neuronal activity in morphine withdrawn rats
15. Mesolimbic dopaminergic decline after cannabinoid withdrawal
16. Cannabinoid receptors and their endogenous agonists
17. Increased motivation for beer in rats following the administration of a cannabinoid CB1 receptor agonist
18. Cannabinoid transmission and reward-related events
19. Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions
20. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
21. Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal
22. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study
23. Morphine-dependent rats: Blockade of precipitated abstinence by tetrahydrocan-nabinol
24. Pharmacology of cannabinoid receptors
25. Behavioural and biochemical evidence for signs of abstinence in mice treated chronically with delta-9-tetrahydrocannabinol
26. Opioids: First lessons from knockout mice
27. Neuroscience of addiction
28. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice
29. Delta-9-tetrahydrocannabinol regulates substance P and enkephalin mRNAs levels in caudate putamen
30. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors
31. Opioid-receptor mRNA expression in the rat CNS: Anatomical and functional implications
32. Pharmacological and biochemical interactions between opioids and cannabinoids
33. Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice
34. Cocaine, but not morphine, induces conditioned place-preference and sensitization to locomotor responses in CB1 knockout mice
35. Antagonism of delta(2)-opioid receptors by naltrindole-5′-isothiocyanate attenuates heroin self-administration but not antinociception in rats
36. 1 receptor knockout mice
37. A diminution of delta-9-tetrahydrocannabinol modulation of dynorphin A(1-17) in conjunction with tolerance development
38. Structure of a cannabinoid receptor and functional expression of the cloned cDNA
39. Localization of cannabinoid receptor mRNA in rat brain
40. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene
41. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors
42. CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats
43. Molecular and cellular basis of addiction
44. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP 55,940 in the spinal cord
45. Molecular mechanisms of opiate receptor coupling to G proteins and effector systems
46. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
47. The dopamine receptor agonist 7-OH-DPAT modulates the acquisition and expression of morphine-induced place preference
48. Activation of Corticotropin-releasing factor in the limbic system during cannabinoid withdrawal
49. Cannabinoid receptor antagonist SR141716a decreases operant ethanol self administration in rats exposed to ethanol-vapor chambers
50. Modulation of rat brain cannabinoid receptors after chronic morphine treatment
51. Long-term treatment with SR141716A, the CB1 receptor antagonist influences morphine withdrawal syndrome
52. Effects of chronic morphine administration on mu opioid receptor-stimulated [35S]GTPγS autoradiography in rat brain
53. Effects of chronic treatment with Δ9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPγS autoradiography in rat brain
54. A second endogenous cannabinoid that modulates long-term potentiation
55. Cannabinoid and heroin activation of mesolimbic dopaminergic transmission by a common μ1 opioid receptor mechanism
56. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys
57. Cloning and pharmacological characterization of a rat mu opioid receptor
58. Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors
59. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine
60. Naltrexone in the treatment of alcohol dependence
61. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice